Monopar Therapeutics (MNPR) Assets Average (2018 - 2026)
Monopar Therapeutics (MNPR) posted Assets Average of $142.5 million for Q4 2025, up 43.85% sequentially from $99.0 million in Q3 2025, and up 329.34% YoY from $33.2 million in Q4 2024.
Monopar Therapeutics (MNPR) Assets Average (2018 - 2026) Analysis & Trends
Monopar Therapeutics has reported Assets Average for 8 years, with the latest figure at $142.5 million in Q4 2025.
- Quarterly Assets Average rose 329.34% year-over-year to $142.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $142.5 million (up 329.34% YoY) and the FY2025 annual result came in at $100.5 million, up 197.19% from the prior year.
- Assets Average rose to $142.5 million in Q4 2025 per MNPR's latest filing, from $99.0 million in the prior quarter.
- Over five years, Assets Average peaked at $142.5 million in Q4 2025 and troughed at $6.6 million in Q3 2024.
- A 5-year average of $30.4 million and a median of $18.3 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average sank 42.4% in 2023, then jumped 1394.88% in 2025.
- Over 5 years, Assets Average stood at $21.5 million in 2021, then plunged by 35.7% to $13.8 million in 2022, then tumbled by 42.4% to $8.0 million in 2023, then surged by 316.36% to $33.2 million in 2024, then jumped by 329.34% to $142.5 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $142.5 million, $99.0 million, and $54.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 137.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.85 Mn |
| Dec 31, 2025 | 142.46 Mn |
| Sep 30, 2025 | 99.03 Mn |
| Jun 30, 2025 | 54.48 Mn |
| Mar 31, 2025 | 57.69 Mn |
| Dec 31, 2024 | 33.18 Mn |
| Sep 30, 2024 | 6.62 Mn |
| Jun 30, 2024 | 8.05 Mn |
| Mar 31, 2024 | 8.13 Mn |
| Dec 31, 2023 | 7.97 Mn |
| Sep 30, 2023 | 9.47 Mn |
| Jun 30, 2023 | 11.09 Mn |
| Mar 31, 2023 | 12.53 Mn |
| Dec 31, 2022 | 13.84 Mn |
| Sep 30, 2022 | 15.59 Mn |
| Jun 30, 2022 | 17.40 Mn |
| Mar 31, 2022 | 19.29 Mn |
| Dec 31, 2021 | 21.52 Mn |
| Sep 30, 2021 | 23.49 Mn |
| Jun 30, 2021 | 25.18 Mn |